{"ticker": {"uuid": "dc902abc-ea97-40f7-98c2-416cf99620c7", "symbol": "SMMT", "name": "Summit Therapeutics PLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale", "summary": "Summit Therapeutics (SMMT; SUMM) has divested its investigational Phase 3 antibiotic, ridinilazole, to Biossil for up to US$104.5 million in milestones, signaling a strategic shift to focus entirely on its oncology drug, ivonescimab. This move comes as the company aims to capital", "url": "https://www.streetwisereports.com/article/2026/07/16/summit-therapeutics-refocuses-on-oncology-drug-after-antibiotic-sale.html", "source_name": "Streetwise Reports", "published_at": "2026-07-17T15:39:47", "published_display": "17 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026", "summary": "Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call on Thursday, July 23, 2026, at 4:30 p.m. EDT to discuss its second-quarter 2026 financial results and operational progress. The biopharmaceutical oncology company, focused on developing medicinal therapies, will ", "url": "https://www.biospace.com/press-releases/summit-therapeutics-to-host-second-quarter-2026-financial-results-operational-progress-call-on-july-23-2026", "source_name": "BioSpace", "published_at": "2026-07-16T14:10:53", "published_display": "16 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics schedules July 23 update on operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPRDVxT2FheVNTWEpra0ltZnUtV3JGeUp5ajF4U0VJQTNod2dXT00wWjVKekgwNHlHUjJhS1BnY05HaTA2R1BSdm1wRUtteU9ub2pEOXR5MTJfTnA0dkN4T1ZVUjBxNm1RZVBEWmd0SHhmSDhMeEhwTi1xc0lybzVtTDZOUWM3bTF4OVV4Q0JoenZsTGs3cW5HVWNWRzRvRWZHNGwyUEJfcTdxbU9ySTNGaWVZVVZNMWRJQ2JrYQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:00:00+00:00", "published_display": "16 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026", "summary": "Summit Therapeutics announced it will host a conference call on July 23, 2026, to discuss its second quarter 2026 financial results and provide an update on operational progress. The call will offer investors and stakeholders insights into the company's recent performance and fut", "url": "https://www.moomoo.com/th/news/post/73076422/press-release-summit-therapeutics-to-host-second-quarter-2026-financial", "source_name": "Moomoo", "published_at": "2026-07-16T12:14:08", "published_display": "16 Jul 2026 12:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal", "summary": "Summit Therapeutics has sold its investigational antibiotic ridinilazole to Biossil Inc. for an upfront payment of US$500,000, with potential future milestones up to US$104.5 million and tiered royalties. While this deal provides a potential long-term income stream and shifts foc", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/the-bull-case-for-summit-therapeutics-smmt-could-change-foll-2", "source_name": "Simply Wall Street", "published_at": "2026-07-15T23:10:54", "published_display": "15 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal", "summary": "Summit Therapeutics has agreed to divest its antibiotic candidate, ridinilazole, to Biossil Inc. for an upfront payment of $500,000 and up to $104.5 million in milestone payments. This divestiture allows Summit to focus on its oncology pipeline, specifically the development of iv", "url": "https://finance.yahoo.com/healthcare/articles/summit-divest-stage-antibiotic-drug-124800925.html", "source_name": "Market source", "published_at": "2026-07-15T12:48:25", "published_display": "15 Jul 2026 12:48", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.", "summary": "Summit Therapeutics has entered an agreement to sell its investigational Phase III antibiotic, ridinilazole, to Biossil, Inc. The deal includes an upfront payment of $500,000 and up to $104.5 million in potential milestone payments and royalties. Ridinilazole is intended for the ", "url": "https://www.biospace.com/press-releases/summit-therapeutics-signs-agreement-to-sell-phase-iii-asset-ridinilazole-to-biossil-inc", "source_name": "BioSpace", "published_at": "2026-07-15T11:09:44", "published_display": "15 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Partners with Biossil for Ridinilazole Sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgJBVV95cUxOUzYyZ0VoVnAxaGVxUFVjdXdnOWxWZ2V1NERPeXpWbUlFNm9ESXZ3MU9HbDlNSDlyWDZGQTJFWmpLYk8yTVhGZmJfUDl2MVdIMVJQbVl0bksyQzF1enMtUTEwLXNLWl9iUDd3bkRsTGJRT1NRajFVbzduRmd0QzJmQ2RDa0tDMWJaTjhMd05veG85NnhSMUk5V2pQcXE2ZERDcmNaWks1UHYwZm1Rak9JNW9EM1c0dHFheEx0ZEtnVTJuTV9vOFpaZUlqbFBub3BkVm5QMUhKcUFFMEZRbjdlVzRtcjQwNFhrWXJPeXlnbm5JU1pVS3NBZ3VqaXVMeDRKU2ktbjZtS1JZbUhZN3FHMnpvb0dsemlsTW8wZHkwZ2VHSFpBbkhBczZZbF9LLWdtVWRqOEFhb0VsVEhabXVIbzFCTDkzQnhyTWJQbDJn?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T02:27:41+00:00", "published_display": "15 Jul 2026 02:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics sells ridinilazole to Biossil for $500k", "summary": "Summit Therapeutics has sold its investigational Phase III antibiotic, ridinilazole, to Biossil, Inc. for an upfront payment of $500,000, with potential milestone payments up to $104.5 million and tiered royalties. This sale allows Summit to focus on its core oncology strategy an", "url": "https://www.investing.com/news/company-news/summit-therapeutics-sells-ridinilazole-to-biossil-for-500k-93CH-4790481", "source_name": "Investing.com", "published_at": "2026-07-14T23:10:54", "published_display": "14 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Sells Phase III Antibiotic Ridinilazole to Biossil in Milestone Deal", "summary": "Summit Therapeutics has sold its Phase III antibiotic, ridinilazole, to Biossil, Inc. for an upfront payment of $500,000 and potential milestone payments of up to $104.5 million. This divestment allows Summit to focus on its oncology pipeline, while Biossil plans to use its AI-en", "url": "https://www.citybiz.co/article/873690/summit-therapeutics-sells-phase-iii-antibiotic-ridinilazole-to-biossil-in-milestone-deal/", "source_name": "citybiz", "published_at": "2026-07-14T22:48:26", "published_display": "14 Jul 2026 22:48", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Summit Therapeutics Inc \u2013 BMV:SMMT", "summary": "This article provides financial information for Summit Therapeutics Inc. (SMMT) on the Mexican Stock Exchange, specifically its forward price-to-earnings ratio. The content is presented as a snapshot from TradingView, indicating no current trades and highlighting financial data a", "url": "https://www.tradingview.com/symbols/BMV-SMMT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T22:48:26", "published_display": "14 Jul 2026 22:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Sells Ridinilazole to Biossil for Up to $105M", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxONXJjejVYeXJVSmQ2LXMyQlhxbEJsODBhRjNJRjhtVnp1OTdZaVotdENYV2N5c2lGbXZhN0F2bmhoTk9OazBnWTd2d3dEdVd0bWp4YnJRZi13Rmh1b09odl9wUFZFd1pkTWs5MlNfSFhkVk9rbDZsRV80VG9ZRWlrMU1BVDAybWtBNlJ2YVdmOTlNLXI1Rmh4Q2dGbE5MVXJIZE45d29CdVFVZDIw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T12:33:21+00:00", "published_display": "14 Jul 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit to sell antibiotic to Canada\u2019s Biossil for up to $105M", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE84blpwXzd0bFdfYm14Tm5wZlJxTkRYbVpqcm8wUVRWNDZjZzdfQW1kcEx0WUNrSDY1ZURiYzMzamFqbG41amprTE9aemczR2lGc3Uta0gwSS1XUjFjMGpMZHg2d1lJNmN1UXBKamM2a2RvY1BWeUVN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T11:33:11+00:00", "published_display": "14 Jul 2026 11:33", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/summit-therapeutics-divests-ridinilazole-asset-112030374.html", "source_name": "MT Newswires", "published_at": "2026-07-14T11:20:30+00:00", "published_display": "14 Jul 2026 11:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 87.99% Potential Upside in Biotechnology", "summary": "Summit Therapeutics Inc. (SMMT), a leading biotechnology firm, shows significant potential with an 87.99% upside predicted by its average target price, despite current unprofitability. The company, focused on groundbreaking cancer therapies like ivonescimab, faces financial chall", "url": "https://www.directorstalkinterviews.com/summit-therapeutics-inc-smmt-stock-analysis-exploring-an-87-99-potential-upside-in-biotechnology/4121256135", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T22:48:26", "published_display": "13 Jul 2026 22:48", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Why (SMMT) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Summit Therapeutics Inc. (NASDAQ: SMMT) with AI-generated trading strategies and multi-timeframe signal analysis. It highlights mixed sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 30.4% gain. The piece provide", "url": "https://news.stocktradersdaily.com/news_release/78/Why_SMMT_Price_Action_Is_Critical_for_Tactical_Trading_071226125402_1783832042.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T00:41:04", "published_display": "12 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Q1 2025 earnings summary", "summary": "Summit Therapeutics (SMMT) announced its Q1 2025 financial results, highlighting significant progress with its bispecific antibody ivonescimab, including expanded regulatory approval in China and positive Phase III trial results for advanced NSCLC. The company ended Q1 2025 with ", "url": "https://quartr.com/events/summit-therapeutics-smmt-q1-2025_FkQBWwcM", "source_name": "Quartr", "published_at": "2026-07-10T01:09:34", "published_display": "10 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 Summary", "summary": "This summary from the Jefferies London Healthcare Conference 2025 highlights Summit Therapeutics' focus on ivonescimab, a PD-1/VEGF bispecific antibody, for cancer treatment. With over 40,000 patients treated globally and 14 ongoing Phase III trials, ivonescimab has demonstrated ", "url": "https://quartr.com/events/summit-therapeutics-inc-smmt-jefferies-london-healthcare-conference-2025_FkQB7sb9", "source_name": "Quartr", "published_at": "2026-07-08T20:51:13", "published_display": "08 Jul 2026 20:51", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Status update Summary", "summary": "Summit Therapeutics (SMMT) has presented strong HARMONi-6 Phase III trial results for Ivonescimab, demonstrating a statistically significant overall survival benefit in advanced squamous NSCLC compared to current treatments. The trial showed a hazard ratio of 0.66 with a median O", "url": "https://quartr.com/events/summit-therapeutics-smmt-status-update_FkQBrPlH", "source_name": "Quartr", "published_at": "2026-07-08T10:10:52", "published_display": "08 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Q4 2024 earnings summary", "summary": "Summit Therapeutics (SMMT) reported its Q4 2024 earnings, highlighting significant progress for its drug ivonescimab, including a new clinical trial collaboration with Pfizer and Fast Track designation for a global Phase III trial. Financially, the company ended 2024 with $412 mi", "url": "https://quartr.com/events/summit-therapeutics-inc-smmt-q4-2024_FkQBWloU", "source_name": "Quartr", "published_at": "2026-07-08T08:41:31", "published_display": "08 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Q3 2025 earnings summary", "summary": "Summit Therapeutics (SMMT) reported its Q3 2025 earnings, highlighting positive clinical trial results for ivonescimab in advanced squamous non-small cell lung cancer which supports a planned BLA submission. Financially, the company ended the quarter with $238.6 million in cash, ", "url": "https://quartr.com/events/summit-therapeutics-inc-smmt-q3-2025_FkQBWf8X", "source_name": "Quartr", "published_at": "2026-07-08T08:41:31", "published_display": "08 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Summit Therapeutics Inc. \u2013 NASDAQ:SMMT", "summary": "This article focuses on the \"Price to sales forward\" metric for Summit Therapeutics Inc. (NASDAQ: SMMT). It presents this financial data point within the context of the company's profile on TradingView. The visible content is limited to the title and basic navigational elements.", "url": "https://www.tradingview.com/symbols/NASDAQ-SMMT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T21:09:07", "published_display": "07 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Summit Therapeutics Inc. \u2013 NASDAQ:SMMT", "summary": "The article provides a snapshot of the \"Price to book forward\" metric for Summit Therapeutics Inc. (NASDAQ: SMMT) on TradingView. It appears to be a financial data point from a larger financial overview of the company, showing its value and change percentages. Most of the content", "url": "https://www.tradingview.com/symbols/NASDAQ-SMMT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T10:40:34", "published_display": "07 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Summit Therapeutics Inc. \u2013 NASDAQ:SMMT", "summary": "This page from TradingView provides a financial overview of Summit Therapeutics Inc. (NASDAQ: SMMT), focusing on its enterprise value to revenue forward metric. It indicates that the market was closed with no trades at the time of viewing. The content includes general financial a", "url": "https://www.tradingview.com/symbols/NASDAQ-SMMT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:12:12", "published_display": "07 Jul 2026 03:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxNZU5Db0VHREF4dmdkeWltQUFCT2dKd2RVMkdNN2FtTEpxSVFUTVhaT0lUZ3VtN3ZiSHJmdmstQ00xTVVHam8zbVJvZFNoOXlTX1RFVFpXQnNBWjY2MjZMdGVJVDh2OFRYNEp3WktCUkEzYTlOUW1rekFYNmxFSjlMME0tREstS09qREFVNHowT2Vla1lYeUg1RFl0ZG5ERy05eUVFdGQ0Qy1XcFNCMWJ1UTBROWJvcG9iQy1yR0h0dlJpUFc2M2FrRG5OcnRJYnJBanl4c1NLQ2NFQmJHajlnd0g4cUhIcVZsbXN1SjR4NkJabnBYUXFsaE1MeUNhYXllQWRVcnVuMWU4ZUNPbER2STl6SG9DVi0zSVRaeVRyc01mZw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-06T23:16:33+00:00", "published_display": "06 Jul 2026 23:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Summit Therapeutics Inc (SMMT)", "summary": "This article provides details on the historical performance of investing $1,000 in Summit Therapeutics Inc. (SMMT) over various periods, showing returns and compound annual growth rates. It also gives an overview of Summit Therapeutics, highlighting its focus on oncology, its lea", "url": "https://www.stocktitan.net/tools/stock-return-calculator/SMMT", "source_name": "Stock Titan", "published_at": "2026-07-04T02:10:06", "published_display": "04 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (SMMT)", "summary": "Quantitative Research Desk has analyzed Summit Therapeutics Inc. (NASDAQ: SMMT), indicating stable neutral readings in shorter horizons may signal an easing of a long-term weak bias. The analysis highlights an exceptional risk-reward setup targeting a 30.3% gain versus 0.3% risk,", "url": "https://news.stocktradersdaily.com/news_release/89/Understanding_Momentum_Shifts_in_SMMT_063026114602_1782877562.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T05:40:31", "published_display": "01 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/d354ac72-d458-36ee-a099-3d257f48a4d5/recursion-pharmaceuticals-vs..html", "source_name": "Motley Fool", "published_at": "2026-06-30T12:05:03+00:00", "published_display": "30 Jun 2026 12:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?", "summary": "Summit Therapeutics (SMMT) recently canceled a US$500 million public offering, causing its shares to fall by over 14% in 30 days, despite significant three-year gains. The cancellation raises questions about the stock's valuation, as some estimates suggest it is 51.2% undervalued", "url": "https://www.sahmcapital.com/news/content/has-summit-therapeutics-smmt-become-undervalued-as-it-pulls-its-500-million-offering-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-27T04:39:54", "published_display": "27 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics finance chief tops list of public CFO pay in 2025", "summary": "Manmeet Soni, CFO of oncology firm Summit Therapeutics, was the highest-paid finance chief among publicly traded American firms in 2025, with total compensation near $250 million. This compensation was largely driven by performance-based stock awards. The report by C-Suite Comp a", "url": "https://www.cfo.com/news/summit-therapeutics-finance-chief-tops-list-of-public-cfo-pay-in-2025-C-Suite-Comp/823544/", "source_name": "CFO.com", "published_at": "2026-06-23T20:39:43", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bernstein raises Summit Therapeutics stock price target on trial outlook", "summary": "Bernstein SocGen Group has increased its price target for Summit Therapeutics (NASDAQ:SMMT) to $9.80 from $7.70, while maintaining an \"Underperform\" rating, based on an increased probability of success for its HARMONi-3 trial. The firm\u2019s analysis assumes that results from Akeso\u2019s", "url": "https://m.investing.com/news/analyst-ratings/bernstein-raises-summit-therapeutics-stock-price-target-on-trial-outlook-93CH-4753125?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-22T14:10:02", "published_display": "22 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing", "summary": "Summit Therapeutics Inc. (SMMT) withdrew a $500 million proposed public offering one day after its announcement, citing unfavorable market conditions. The offering was intended to fund research and development for ivonescimab, a bispecific antibody for cancer treatment that recen", "url": "https://finance.yahoo.com/healthcare/articles/summit-therapeutics-smmt-500-million-141316716.html", "source_name": "Market source", "published_at": "2026-06-22T14:10:01", "published_display": "22 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPaDFpdlBpTkF4VzJKWU1fb3NFeVNUTTd2bkZMczdwcGd3bVVvV0pxWS1FSmV2aWxWNWpXb1VHdDdXZEJvTURhN0dVSnNyZ2h0NkNZWkktT2puWWJET3RMa3VSQzNBdW1qNncySE8xSHRBZ1BXWkJsZE02d29yU0RWMGJWNzFUSUZibmVidXE3WmdnaUtuQUY5NUhvUFZWX1VjRHZJYV9n?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Most Promising Healthcare Stocks According to Wall Street Analysts", "summary": "This article identifies Summit Therapeutics Inc. (NASDAQ: SMMT) as one of the most promising healthcare stocks according to Wall Street analysts. Summit's lead drug, ivonescimab, which targets cancer cells, recently showed positive Phase 3 data from a China-based lung cancer tria", "url": "https://www.insidermonkey.com/blog/5-most-promising-healthcare-stocks-according-to-wall-street-analysts-1784463/5/", "source_name": "Insider Monkey", "published_at": "2026-06-21T00:10:24", "published_display": "21 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Summit Therapeutics Inc (SMMT), detailing its revenue breakdown, profitability margins, and a comparison with competitors like BMRN and ARWR. The company currently has no data on its revenue streams, and its gross, operating, and net ", "url": "https://intellectia.ai/en/stock/SMMT/financials", "source_name": "Intellectia AI", "published_at": "2026-06-20T08:09:44", "published_display": "20 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (SMMT) Movement", "summary": "Stock Traders Daily's Quantitative Research Desk provides an analysis of Summit Therapeutics Inc. (SMMT), highlighting near-term strong sentiment challenging persistent mid and long-term weakness. The article details an exceptional 87.0:1 risk-reward short setup and offers three ", "url": "https://news.stocktradersdaily.com/news_release/90/Avoiding_Lag:_Real-Time_Signals_in_SMMT_Movement_061926103402_1781922842.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T22:34:00", "published_display": "19 Jun 2026 22:34", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Summit Therapeutics Inc (SMMT) has an earnings forecast score of 7.22, placing it in the 308th position out of 389 companies in the Biotechnology & Medical Research industry. Analysts have set an average price target of $34.50 for SMMT, with ratings predominantly suggesting a \"Bu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-smmt/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T06:39:51", "published_display": "19 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Summit Therapeutics\u2019 Canceled US$500 Million Equity Offering Reshape SMMT Investors\u2019 View on Financing Strategy?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/summit-therapeutics-smmt-raises-500-152846985.html", "source_name": "Insider Monkey", "published_at": "2026-06-13T15:28:46+00:00", "published_display": "13 Jun 2026 15:28", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Summit Therapeutics Co-CEO, President & Director Bought US$1.5m Of Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Insider Bought Shares Worth $49,987,200, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/summit-therapeutics-insider-bought-shares-163558734.html", "source_name": "MT Newswires", "published_at": "2026-06-12T16:35:58+00:00", "published_display": "12 Jun 2026 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZVVnMUNQT0ZaUDNOVHB3djM1SVNDd3ViOWhSbGtvQ2tsakRVbWZRZGNvMHgzVFQyR2dEQVR5X3I1RW9jYm5QaXNZQjJnLTN2bVdzN1FYUEZudTByN24tUjNUY0dCOURMQ1hfX3JBdG1JU0t1SF9XOFZicVBONVk1YVo4REpZUVp4NUc3LU1WejdsZ3Y5RTllUTVtWlRrZTZuMUpzVko5MXlfeHNwMGpybDh6WmNWU3Iy?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNdGh6ZF9Pa0lZVlJDUTR4QXVselp1Umt2UTRuY3ZzUlNaSVJZYW03Q3FtZWxqSDBIVGtadWV6aFRjMmxtdlBaRzdqZlRFTVpNUG9zQlh6dHU5WEFfSUZ3OWNaWDI3MVRfdnluWUdhZ2g0MlhYZHJfNnVhYjZsRloyM0Z6NHJfb1ZKcDFNMnlSTEZoUkhFRHBSRlNoRTlXb0VyQ1VWUw?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Withdraws Public Offering Amid Market Conditions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPZXZIQkZiVTg5OXdSQ01sQ0pZZHE1aTdjSUMtdDdVWVpYYWVGQXVJTnB1T3dtTWhtUlZzMEljeVFkY2tGbERJYUg4YmVIQ2VEWU5wZmNFaEpsWUxYSXhMbFluMFEtbmtzTExXc1ducjBxM2FrSUR4c0ZNU3NBcm03UGlmRWJJSzRjb0QteTZUWUhIZkM0LXNzSjd6aGpQQnRQOEZnZ2lXOGI3NkZYdy1SaUNFY0N1SVN0Mmd6RW11T2pXN3RoOGFKQ01QM0RMZWExc2thcnR2VnE4RTZiVi1YcG9BMjFxMEk?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (NASDAQ: SMMT) pulls planned stock sale amid markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQeWpyVzFuRURseDJzOXplS0c0QjhUZzRoUU11cTNYRDFORmtQcWM3SjYyV18xOVM1ekdFM2VnQmdfSTFwX2lXYVFsLWo2dDZ0UGQ0VmZfd2VqYVVXUnZQQkN0bjJZUDdtZERsYWNYSEd6ZmhsXzlFeTYtSy16SW9ieWd6eUo1bFZodjNCbTBaMjZySFBFNjZJcHpNTFpWOWh5UnNBNHZMaUZoMG0xT2VnOExR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) seeks $500M equity raise; ASCO trial wins highlighted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNY2lTSkVjaUx5TVdNSnYwa1NYdFpUM2dpSGhpZk1EQjlSMUJidkV2bkFKUEpPcDJSYjd0T05lUmJRY3hmQW9rVVRJcGRjd2p2NHpiY211czNWVjBRTHoyN0p2VHRMc3Rxek1jREJRRUI4ajQwTk5RVWpZZlpBeDBkY0dGN2FFV1BvaFVPbTBLaXVjbjVKbXFNQUVnT29UcktkQk0yMjgyVGhlU1paWXE3MEstRU5jamtGcUJ1X0dJVFEtWUF6eTVTZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNeExRUzUzanNCaEVvLVh2Q0duSlBoYWxvRmRXR3RQeHpsTzJhYm11VXlnQ08zM0dVVnNVcV85WVpYMDRGeEdrMUl6a3lZcHlETkZEd2JScFlFNUhwcElTTEhwRU1wWUttbktBZ0hCaXc0c0hoZktNQWY4NjFsVy1RNDhFeG92MHFvVDgxdERYcFkyeWk4dW02UXVybmNCMW1GVV84?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) co-CEO buys 100K shares via revocable trust", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOV3huODBXSXhEd253dkFaVE1RckhIMWNZMi1CUWZPa3BQWFpxRTVZVUpCU3czM1FYY3lDZEdSMUN0RWY3RWxjNHB3S2Q3ZmxaSFF0VlVaV0QwMm03RnM0WXdDREdOcmlYN0E4ZFVqNUt3N056ZG5WQ3lEYUoyQmpNZ3lqbDdMb2Z2UzU5OHZSLVNabEJxZFp6MXlnZGFPUGg3VzVxNTRhWEkxMVE3N18zSjlCZTJQakln?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) leaders may buy shares via existing ATM", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbXF4dlFRZm91RjZqUzFzX19qdHplS2xqQ0xkQktQN3hZMXo3LVVidVc5dFlydUxqLUNHaW1XRXlFTmxReEk4ZDZQZWM3Mm1HWTFYQl9xeEI2em1fektfVWZIeEFnTnlGbnlQUXBjSDNLUXF6TzdIYk5WZ1F3WndLcU1oSmhvS1pPRjd1SEdWQTgwM21oMHVqRy1sV3lpc0NBdWpISFFESWNSVUlkRUkybUF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNd0xiYmlwMVdwMTdmaEx3eXF0OXJNR29mWi02UmF2U3dveG5RRmJjczQ2dnJFZms5MXZnRk5tcHlUVjRvcnNBUmNHQ3NfdjJuOE1fdmZlOUd3OGJSejlXclJHTlRRdnFVNXhHbUFmZVZocXBkbE02SXo4S0JRZVIwLXI1YkRiT2hkZjU0V0std0JsZ1ZPSVQwQ2RwalByU0lqbnNlcERxTThOTXpNTHc?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPX1hDOEk5SWpudE1lNTFyOWxXemswcGt4WjJvWG05TUxzVGlVUzk3aENobFJlSlZHMjBnZzhGZVFETDUxRHBWcU93dXYzSnJXMGdCTEpIMy1BcjItTmd5dU9XY252azNjZ0JGb1l0eWVvMzFBZDV4dmFocmQ3ZDZtVmJJRXBYek12Mkp2cWw1a3JoVi03UGZOZUYxbVJrYzUz?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale", "summary": "Summit Therapeutics (SMMT; SUMM) has divested its investigational Phase 3 antibiotic, ridinilazole, to Biossil for up to US$104.5 million in milestones, signaling a strategic shift to focus entirely on its oncology drug, ivonescimab. This move comes as the company aims to capital", "url": "https://www.streetwisereports.com/article/2026/07/16/summit-therapeutics-refocuses-on-oncology-drug-after-antibiotic-sale.html", "source_name": "Streetwise Reports", "published_at": "2026-07-17T15:39:47", "published_display": "17 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026", "summary": "Summit Therapeutics Inc. (Nasdaq: SMMT) will host a conference call on Thursday, July 23, 2026, at 4:30 p.m. EDT to discuss its second-quarter 2026 financial results and operational progress. The biopharmaceutical oncology company, focused on developing medicinal therapies, will ", "url": "https://www.biospace.com/press-releases/summit-therapeutics-to-host-second-quarter-2026-financial-results-operational-progress-call-on-july-23-2026", "source_name": "BioSpace", "published_at": "2026-07-16T14:10:53", "published_display": "16 Jul 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics schedules July 23 update on operations", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPRDVxT2FheVNTWEpra0ltZnUtV3JGeUp5ajF4U0VJQTNod2dXT00wWjVKekgwNHlHUjJhS1BnY05HaTA2R1BSdm1wRUtteU9ub2pEOXR5MTJfTnA0dkN4T1ZVUjBxNm1RZVBEWmd0SHhmSDhMeEhwTi1xc0lybzVtTDZOUWM3bTF4OVV4Q0JoenZsTGs3cW5HVWNWRzRvRWZHNGwyUEJfcTdxbU9ySTNGaWVZVVZNMWRJQ2JrYQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-16T12:00:00+00:00", "published_display": "16 Jul 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026", "summary": "Summit Therapeutics announced it will host a conference call on July 23, 2026, to discuss its second quarter 2026 financial results and provide an update on operational progress. The call will offer investors and stakeholders insights into the company's recent performance and fut", "url": "https://www.moomoo.com/th/news/post/73076422/press-release-summit-therapeutics-to-host-second-quarter-2026-financial", "source_name": "Moomoo", "published_at": "2026-07-16T12:14:08", "published_display": "16 Jul 2026 12:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For Summit Therapeutics (SMMT) Could Change Following Ridinilazole Sale And Royalty Deal", "summary": "Summit Therapeutics has sold its investigational antibiotic ridinilazole to Biossil Inc. for an upfront payment of US$500,000, with potential future milestones up to US$104.5 million and tiered royalties. While this deal provides a potential long-term income stream and shifts foc", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-smmt/summit-therapeutics/news/the-bull-case-for-summit-therapeutics-smmt-could-change-foll-2", "source_name": "Simply Wall Street", "published_at": "2026-07-15T23:10:54", "published_display": "15 Jul 2026 23:10", "sentiment": "positive", "sentiment_pct": 59, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal", "summary": "Summit Therapeutics has agreed to divest its antibiotic candidate, ridinilazole, to Biossil Inc. for an upfront payment of $500,000 and up to $104.5 million in milestone payments. This divestiture allows Summit to focus on its oncology pipeline, specifically the development of iv", "url": "https://finance.yahoo.com/healthcare/articles/summit-divest-stage-antibiotic-drug-124800925.html", "source_name": "Market source", "published_at": "2026-07-15T12:48:25", "published_display": "15 Jul 2026 12:48", "sentiment": "positive", "sentiment_pct": 61, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.", "summary": "Summit Therapeutics has entered an agreement to sell its investigational Phase III antibiotic, ridinilazole, to Biossil, Inc. The deal includes an upfront payment of $500,000 and up to $104.5 million in potential milestone payments and royalties. Ridinilazole is intended for the ", "url": "https://www.biospace.com/press-releases/summit-therapeutics-signs-agreement-to-sell-phase-iii-asset-ridinilazole-to-biossil-inc", "source_name": "BioSpace", "published_at": "2026-07-15T11:09:44", "published_display": "15 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Partners with Biossil for Ridinilazole Sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgJBVV95cUxOUzYyZ0VoVnAxaGVxUFVjdXdnOWxWZ2V1NERPeXpWbUlFNm9ESXZ3MU9HbDlNSDlyWDZGQTJFWmpLYk8yTVhGZmJfUDl2MVdIMVJQbVl0bksyQzF1enMtUTEwLXNLWl9iUDd3bkRsTGJRT1NRajFVbzduRmd0QzJmQ2RDa0tDMWJaTjhMd05veG85NnhSMUk5V2pQcXE2ZERDcmNaWks1UHYwZm1Rak9JNW9EM1c0dHFheEx0ZEtnVTJuTV9vOFpaZUlqbFBub3BkVm5QMUhKcUFFMEZRbjdlVzRtcjQwNFhrWXJPeXlnbm5JU1pVS3NBZ3VqaXVMeDRKU2ktbjZtS1JZbUhZN3FHMnpvb0dsemlsTW8wZHkwZ2VHSFpBbkhBczZZbF9LLWdtVWRqOEFhb0VsVEhabXVIbzFCTDkzQnhyTWJQbDJn?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-15T02:27:41+00:00", "published_display": "15 Jul 2026 02:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics sells ridinilazole to Biossil for $500k", "summary": "Summit Therapeutics has sold its investigational Phase III antibiotic, ridinilazole, to Biossil, Inc. for an upfront payment of $500,000, with potential milestone payments up to $104.5 million and tiered royalties. This sale allows Summit to focus on its core oncology strategy an", "url": "https://www.investing.com/news/company-news/summit-therapeutics-sells-ridinilazole-to-biossil-for-500k-93CH-4790481", "source_name": "Investing.com", "published_at": "2026-07-14T23:10:54", "published_display": "14 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Sells Phase III Antibiotic Ridinilazole to Biossil in Milestone Deal", "summary": "Summit Therapeutics has sold its Phase III antibiotic, ridinilazole, to Biossil, Inc. for an upfront payment of $500,000 and potential milestone payments of up to $104.5 million. This divestment allows Summit to focus on its oncology pipeline, while Biossil plans to use its AI-en", "url": "https://www.citybiz.co/article/873690/summit-therapeutics-sells-phase-iii-antibiotic-ridinilazole-to-biossil-in-milestone-deal/", "source_name": "citybiz", "published_at": "2026-07-14T22:48:26", "published_display": "14 Jul 2026 22:48", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Summit Therapeutics Inc \u2013 BMV:SMMT", "summary": "This article provides financial information for Summit Therapeutics Inc. (SMMT) on the Mexican Stock Exchange, specifically its forward price-to-earnings ratio. The content is presented as a snapshot from TradingView, indicating no current trades and highlighting financial data a", "url": "https://www.tradingview.com/symbols/BMV-SMMT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-14T22:48:26", "published_display": "14 Jul 2026 22:48", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Sells Ridinilazole to Biossil for Up to $105M", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxONXJjejVYeXJVSmQ2LXMyQlhxbEJsODBhRjNJRjhtVnp1OTdZaVotdENYV2N5c2lGbXZhN0F2bmhoTk9OazBnWTd2d3dEdVd0bWp4YnJRZi13Rmh1b09odl9wUFZFd1pkTWs5MlNfSFhkVk9rbDZsRV80VG9ZRWlrMU1BVDAybWtBNlJ2YVdmOTlNLXI1Rmh4Q2dGbE5MVXJIZE45d29CdVFVZDIw?oc=5", "source_name": "GuruFocus", "published_at": "2026-07-14T12:33:21+00:00", "published_display": "14 Jul 2026 12:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit to sell antibiotic to Canada\u2019s Biossil for up to $105M", "summary": "", "url": "https://news.google.com/rss/articles/CBMid0FVX3lxTE84blpwXzd0bFdfYm14Tm5wZlJxTkRYbVpqcm8wUVRWNDZjZzdfQW1kcEx0WUNrSDY1ZURiYzMzamFqbG41amprTE9aemczR2lGc3Uta0gwSS1XUjFjMGpMZHg2d1lJNmN1UXBKamM2a2RvY1BWeUVN?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-14T11:33:11+00:00", "published_display": "14 Jul 2026 11:33", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Divests Ridinilazole Asset to AI Biopharma Biossil", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/summit-therapeutics-divests-ridinilazole-asset-112030374.html", "source_name": "MT Newswires", "published_at": "2026-07-14T11:20:30+00:00", "published_display": "14 Jul 2026 11:20", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring an 87.99% Potential Upside in Biotechnology", "summary": "Summit Therapeutics Inc. (SMMT), a leading biotechnology firm, shows significant potential with an 87.99% upside predicted by its average target price, despite current unprofitability. The company, focused on groundbreaking cancer therapies like ivonescimab, faces financial chall", "url": "https://www.directorstalkinterviews.com/summit-therapeutics-inc-smmt-stock-analysis-exploring-an-87-99-potential-upside-in-biotechnology/4121256135", "source_name": "DirectorsTalk Interviews", "published_at": "2026-07-13T22:48:26", "published_display": "13 Jul 2026 22:48", "sentiment": "positive", "sentiment_pct": 63, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (SMMT) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Summit Therapeutics Inc. (NASDAQ: SMMT) with AI-generated trading strategies and multi-timeframe signal analysis. It highlights mixed sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward setup targeting a 30.4% gain. The piece provide", "url": "https://news.stocktradersdaily.com/news_release/78/Why_SMMT_Price_Action_Is_Critical_for_Tactical_Trading_071226125402_1783832042.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-12T00:41:04", "published_display": "12 Jul 2026 00:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Q1 2025 earnings summary", "summary": "Summit Therapeutics (SMMT) announced its Q1 2025 financial results, highlighting significant progress with its bispecific antibody ivonescimab, including expanded regulatory approval in China and positive Phase III trial results for advanced NSCLC. The company ended Q1 2025 with ", "url": "https://quartr.com/events/summit-therapeutics-smmt-q1-2025_FkQBWwcM", "source_name": "Quartr", "published_at": "2026-07-10T01:09:34", "published_display": "10 Jul 2026 01:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Jefferies London Healthcare Conference 2025 Summary", "summary": "This summary from the Jefferies London Healthcare Conference 2025 highlights Summit Therapeutics' focus on ivonescimab, a PD-1/VEGF bispecific antibody, for cancer treatment. With over 40,000 patients treated globally and 14 ongoing Phase III trials, ivonescimab has demonstrated ", "url": "https://quartr.com/events/summit-therapeutics-inc-smmt-jefferies-london-healthcare-conference-2025_FkQB7sb9", "source_name": "Quartr", "published_at": "2026-07-08T20:51:13", "published_display": "08 Jul 2026 20:51", "sentiment": "positive", "sentiment_pct": 95, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Status update Summary", "summary": "Summit Therapeutics (SMMT) has presented strong HARMONi-6 Phase III trial results for Ivonescimab, demonstrating a statistically significant overall survival benefit in advanced squamous NSCLC compared to current treatments. The trial showed a hazard ratio of 0.66 with a median O", "url": "https://quartr.com/events/summit-therapeutics-smmt-status-update_FkQBrPlH", "source_name": "Quartr", "published_at": "2026-07-08T10:10:52", "published_display": "08 Jul 2026 10:10", "sentiment": "positive", "sentiment_pct": 95, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Q4 2024 earnings summary", "summary": "Summit Therapeutics (SMMT) reported its Q4 2024 earnings, highlighting significant progress for its drug ivonescimab, including a new clinical trial collaboration with Pfizer and Fast Track designation for a global Phase III trial. Financially, the company ended 2024 with $412 mi", "url": "https://quartr.com/events/summit-therapeutics-inc-smmt-q4-2024_FkQBWloU", "source_name": "Quartr", "published_at": "2026-07-08T08:41:31", "published_display": "08 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Q3 2025 earnings summary", "summary": "Summit Therapeutics (SMMT) reported its Q3 2025 earnings, highlighting positive clinical trial results for ivonescimab in advanced squamous non-small cell lung cancer which supports a planned BLA submission. Financially, the company ended the quarter with $238.6 million in cash, ", "url": "https://quartr.com/events/summit-therapeutics-inc-smmt-q3-2025_FkQBWf8X", "source_name": "Quartr", "published_at": "2026-07-08T08:41:31", "published_display": "08 Jul 2026 08:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Summit Therapeutics Inc. \u2013 NASDAQ:SMMT", "summary": "This article focuses on the \"Price to sales forward\" metric for Summit Therapeutics Inc. (NASDAQ: SMMT). It presents this financial data point within the context of the company's profile on TradingView. The visible content is limited to the title and basic navigational elements.", "url": "https://www.tradingview.com/symbols/NASDAQ-SMMT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T21:09:07", "published_display": "07 Jul 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Summit Therapeutics Inc. \u2013 NASDAQ:SMMT", "summary": "The article provides a snapshot of the \"Price to book forward\" metric for Summit Therapeutics Inc. (NASDAQ: SMMT) on TradingView. It appears to be a financial data point from a larger financial overview of the company, showing its value and change percentages. Most of the content", "url": "https://www.tradingview.com/symbols/NASDAQ-SMMT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T10:40:34", "published_display": "07 Jul 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Summit Therapeutics Inc. \u2013 NASDAQ:SMMT", "summary": "This page from TradingView provides a financial overview of Summit Therapeutics Inc. (NASDAQ: SMMT), focusing on its enterprise value to revenue forward metric. It indicates that the market was closed with no trades at the time of viewing. The content includes general financial a", "url": "https://www.tradingview.com/symbols/NASDAQ-SMMT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-07T03:12:12", "published_display": "07 Jul 2026 03:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogJBVV95cUxNZU5Db0VHREF4dmdkeWltQUFCT2dKd2RVMkdNN2FtTEpxSVFUTVhaT0lUZ3VtN3ZiSHJmdmstQ00xTVVHam8zbVJvZFNoOXlTX1RFVFpXQnNBWjY2MjZMdGVJVDh2OFRYNEp3WktCUkEzYTlOUW1rekFYNmxFSjlMME0tREstS09qREFVNHowT2Vla1lYeUg1RFl0ZG5ERy05eUVFdGQ0Qy1XcFNCMWJ1UTBROWJvcG9iQy1yR0h0dlJpUFc2M2FrRG5OcnRJYnJBanl4c1NLQ2NFQmJHajlnd0g4cUhIcVZsbXN1SjR4NkJabnBYUXFsaE1MeUNhYXllQWRVcnVuMWU4ZUNPbER2STl6SG9DVi0zSVRaeVRyc01mZw?oc=5", "source_name": "Moomoo", "published_at": "2026-07-06T23:16:33+00:00", "published_display": "06 Jul 2026 23:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "If You Invested $1,000 in Summit Therapeutics Inc (SMMT)", "summary": "This article provides details on the historical performance of investing $1,000 in Summit Therapeutics Inc. (SMMT) over various periods, showing returns and compound annual growth rates. It also gives an overview of Summit Therapeutics, highlighting its focus on oncology, its lea", "url": "https://www.stocktitan.net/tools/stock-return-calculator/SMMT", "source_name": "Stock Titan", "published_at": "2026-07-04T02:10:06", "published_display": "04 Jul 2026 02:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Understanding Momentum Shifts in (SMMT)", "summary": "Quantitative Research Desk has analyzed Summit Therapeutics Inc. (NASDAQ: SMMT), indicating stable neutral readings in shorter horizons may signal an easing of a long-term weak bias. The analysis highlights an exceptional risk-reward setup targeting a 30.3% gain versus 0.3% risk,", "url": "https://news.stocktradersdaily.com/news_release/89/Understanding_Momentum_Shifts_in_SMMT_063026114602_1782877562.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-01T05:40:31", "published_display": "01 Jul 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?", "summary": "", "url": "https://finance.yahoo.com/m/d354ac72-d458-36ee-a099-3d257f48a4d5/recursion-pharmaceuticals-vs..html", "source_name": "Motley Fool", "published_at": "2026-06-30T12:05:03+00:00", "published_display": "30 Jun 2026 12:05", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Has Summit Therapeutics (SMMT) Become Undervalued As It Pulls Its $500 Million Offering?", "summary": "Summit Therapeutics (SMMT) recently canceled a US$500 million public offering, causing its shares to fall by over 14% in 30 days, despite significant three-year gains. The cancellation raises questions about the stock's valuation, as some estimates suggest it is 51.2% undervalued", "url": "https://www.sahmcapital.com/news/content/has-summit-therapeutics-smmt-become-undervalued-as-it-pulls-its-500-million-offering-2026-06-25", "source_name": "Sahm", "published_at": "2026-06-27T04:39:54", "published_display": "27 Jun 2026 04:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics finance chief tops list of public CFO pay in 2025", "summary": "Manmeet Soni, CFO of oncology firm Summit Therapeutics, was the highest-paid finance chief among publicly traded American firms in 2025, with total compensation near $250 million. This compensation was largely driven by performance-based stock awards. The report by C-Suite Comp a", "url": "https://www.cfo.com/news/summit-therapeutics-finance-chief-tops-list-of-public-cfo-pay-in-2025-C-Suite-Comp/823544/", "source_name": "CFO.com", "published_at": "2026-06-23T20:39:43", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bernstein raises Summit Therapeutics stock price target on trial outlook", "summary": "Bernstein SocGen Group has increased its price target for Summit Therapeutics (NASDAQ:SMMT) to $9.80 from $7.70, while maintaining an \"Underperform\" rating, based on an increased probability of success for its HARMONi-3 trial. The firm\u2019s analysis assumes that results from Akeso\u2019s", "url": "https://m.investing.com/news/analyst-ratings/bernstein-raises-summit-therapeutics-stock-price-target-on-trial-outlook-93CH-4753125?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-22T14:10:02", "published_display": "22 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT): A $500 Million Stock Offering Pulled Just One Day After Filing", "summary": "Summit Therapeutics Inc. (SMMT) withdrew a $500 million proposed public offering one day after its announcement, citing unfavorable market conditions. The offering was intended to fund research and development for ivonescimab, a bispecific antibody for cancer treatment that recen", "url": "https://finance.yahoo.com/healthcare/articles/summit-therapeutics-smmt-500-million-141316716.html", "source_name": "Market source", "published_at": "2026-06-22T14:10:01", "published_display": "22 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics: High-Volatility, Catalyst-Driven Binary Bet (NASDAQ:SMMT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxPaDFpdlBpTkF4VzJKWU1fb3NFeVNUTTd2bkZMczdwcGd3bVVvV0pxWS1FSmV2aWxWNWpXb1VHdDdXZEJvTURhN0dVSnNyZ2h0NkNZWkktT2puWWJET3RMa3VSQzNBdW1qNncySE8xSHRBZ1BXWkJsZE02d29yU0RWMGJWNzFUSUZibmVidXE3WmdnaUtuQUY5NUhvUFZWX1VjRHZJYV9n?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Most Promising Healthcare Stocks According to Wall Street Analysts", "summary": "This article identifies Summit Therapeutics Inc. (NASDAQ: SMMT) as one of the most promising healthcare stocks according to Wall Street analysts. Summit's lead drug, ivonescimab, which targets cancer cells, recently showed positive Phase 3 data from a China-based lung cancer tria", "url": "https://www.insidermonkey.com/blog/5-most-promising-healthcare-stocks-according-to-wall-street-analysts-1784463/5/", "source_name": "Insider Monkey", "published_at": "2026-06-21T00:10:24", "published_display": "21 Jun 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SMMT Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a financial overview of Summit Therapeutics Inc (SMMT), detailing its revenue breakdown, profitability margins, and a comparison with competitors like BMRN and ARWR. The company currently has no data on its revenue streams, and its gross, operating, and net ", "url": "https://intellectia.ai/en/stock/SMMT/financials", "source_name": "Intellectia AI", "published_at": "2026-06-20T08:09:44", "published_display": "20 Jun 2026 08:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Avoiding Lag: Real-Time Signals in (SMMT) Movement", "summary": "Stock Traders Daily's Quantitative Research Desk provides an analysis of Summit Therapeutics Inc. (SMMT), highlighting near-term strong sentiment challenging persistent mid and long-term weakness. The article details an exceptional 87.0:1 risk-reward short setup and offers three ", "url": "https://news.stocktradersdaily.com/news_release/90/Avoiding_Lag:_Real-Time_Signals_in_SMMT_Movement_061926103402_1781922842.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-19T22:34:00", "published_display": "19 Jun 2026 22:34", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Inc (SMMT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Summit Therapeutics Inc (SMMT) has an earnings forecast score of 7.22, placing it in the 308th position out of 389 companies in the Biotechnology & Medical Research industry. Analysts have set an average price target of $34.50 for SMMT, with ratings predominantly suggesting a \"Bu", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-smmt/earnings", "source_name": "TradingKey", "published_at": "2026-06-19T06:39:51", "published_display": "19 Jun 2026 06:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Summit Therapeutics\u2019 Canceled US$500 Million Equity Offering Reshape SMMT Investors\u2019 View on Financing Strategy?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-16T07:00:00+00:00", "published_display": "16 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Raises $500 Million Through Public Offering", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/summit-therapeutics-smmt-raises-500-152846985.html", "source_name": "Insider Monkey", "published_at": "2026-06-13T15:28:46+00:00", "published_display": "13 Jun 2026 15:28", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Buying: Summit Therapeutics Co-CEO, President & Director Bought US$1.5m Of Shares", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-13T07:00:00+00:00", "published_display": "13 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Insider Bought Shares Worth $49,987,200, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/summit-therapeutics-insider-bought-shares-163558734.html", "source_name": "MT Newswires", "published_at": "2026-06-12T16:35:58+00:00", "published_display": "12 Jun 2026 16:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Co-CEO Robert Duggan buys 3.81M shares in open market", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOZVVnMUNQT0ZaUDNOVHB3djM1SVNDd3ViOWhSbGtvQ2tsakRVbWZRZGNvMHgzVFQyR2dEQVR5X3I1RW9jYm5QaXNZQjJnLTN2bVdzN1FYUEZudTByN24tUjNUY0dCOURMQ1hfX3JBdG1JU0t1SF9XOFZicVBONVk1YVo4REpZUVp4NUc3LU1WejdsZ3Y5RTllUTVtWlRrZTZuMUpzVko5MXlfeHNwMGpybDh6WmNWU3Iy?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics Halts US$500m Offering After Ivonescimab Trial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNdGh6ZF9Pa0lZVlJDUTR4QXVselp1Umt2UTRuY3ZzUlNaSVJZYW03Q3FtZWxqSDBIVGtadWV6aFRjMmxtdlBaRzdqZlRFTVpNUG9zQlh6dHU5WEFfSUZ3OWNaWDI3MVRfdnluWUdhZ2g0MlhYZHJfNnVhYjZsRloyM0Z6NHJfb1ZKcDFNMnlSTEZoUkhFRHBSRlNoRTlXb0VyQ1VWUw?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) Withdraws Public Offering Amid Market Conditions", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxPZXZIQkZiVTg5OXdSQ01sQ0pZZHE1aTdjSUMtdDdVWVpYYWVGQXVJTnB1T3dtTWhtUlZzMEljeVFkY2tGbERJYUg4YmVIQ2VEWU5wZmNFaEpsWUxYSXhMbFluMFEtbmtzTExXc1ducjBxM2FrSUR4c0ZNU3NBcm03UGlmRWJJSzRjb0QteTZUWUhIZkM0LXNzSjd6aGpQQnRQOEZnZ2lXOGI3NkZYdy1SaUNFY0N1SVN0Mmd6RW11T2pXN3RoOGFKQ01QM0RMZWExc2thcnR2VnE4RTZiVi1YcG9BMjFxMEk?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (NASDAQ: SMMT) pulls planned stock sale amid markets", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQeWpyVzFuRURseDJzOXplS0c0QjhUZzRoUU11cTNYRDFORmtQcWM3SjYyV18xOVM1ekdFM2VnQmdfSTFwX2lXYVFsLWo2dDZ0UGQ0VmZfd2VqYVVXUnZQQkN0bjJZUDdtZERsYWNYSEd6ZmhsXzlFeTYtSy16SW9ieWd6eUo1bFZodjNCbTBaMjZySFBFNjZJcHpNTFpWOWh5UnNBNHZMaUZoMG0xT2VnOExR?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) seeks $500M equity raise; ASCO trial wins highlighted", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxNY2lTSkVjaUx5TVdNSnYwa1NYdFpUM2dpSGhpZk1EQjlSMUJidkV2bkFKUEpPcDJSYjd0T05lUmJRY3hmQW9rVVRJcGRjd2p2NHpiY211czNWVjBRTHoyN0p2VHRMc3Rxek1jREJRRUI4ajQwTk5RVWpZZlpBeDBkY0dGN2FFV1BvaFVPbTBLaXVjbjVKbXFNQUVnT29UcktkQk0yMjgyVGhlU1paWXE3MEstRU5jamtGcUJ1X0dJVFEtWUF6eTVTZQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNeExRUzUzanNCaEVvLVh2Q0duSlBoYWxvRmRXR3RQeHpsTzJhYm11VXlnQ08zM0dVVnNVcV85WVpYMDRGeEdrMUl6a3lZcHlETkZEd2JScFlFNUhwcElTTEhwRU1wWUttbktBZ0hCaXc0c0hoZktNQWY4NjFsVy1RNDhFeG92MHFvVDgxdERYcFkyeWk4dW02UXVybmNCMW1GVV84?oc=5", "source_name": "Market source", "published_at": "2026-06-07T07:00:00+00:00", "published_display": "07 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) co-CEO buys 100K shares via revocable trust", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOV3huODBXSXhEd253dkFaVE1RckhIMWNZMi1CUWZPa3BQWFpxRTVZVUpCU3czM1FYY3lDZEdSMUN0RWY3RWxjNHB3S2Q3ZmxaSFF0VlVaV0QwMm03RnM0WXdDREdOcmlYN0E4ZFVqNUt3N056ZG5WQ3lEYUoyQmpNZ3lqbDdMb2Z2UzU5OHZSLVNabEJxZFp6MXlnZGFPUGg3VzVxNTRhWEkxMVE3N18zSjlCZTJQakln?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Summit Therapeutics (SMMT) leaders may buy shares via existing ATM", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPbXF4dlFRZm91RjZqUzFzX19qdHplS2xqQ0xkQktQN3hZMXo3LVVidVc5dFlydUxqLUNHaW1XRXlFTmxReEk4ZDZQZWM3Mm1HWTFYQl9xeEI2em1fektfVWZIeEFnTnlGbnlQUXBjSDNLUXF6TzdIYk5WZ1F3WndLcU1oSmhvS1pPRjd1SEdWQTgwM21oMHVqRy1sV3lpc0NBdWpISFFESWNSVUlkRUkybUF3?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNd0xiYmlwMVdwMTdmaEx3eXF0OXJNR29mWi02UmF2U3dveG5RRmJjczQ2dnJFZms5MXZnRk5tcHlUVjRvcnNBUmNHQ3NfdjJuOE1fdmZlOUd3OGJSejlXclJHTlRRdnFVNXhHbUFmZVZocXBkbE02SXo4S0JRZVIwLXI1YkRiT2hkZjU0V0std0JsZ1ZPSVQwQ2RwalByU0lqbnNlcERxTThOTXpNTHc?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From Now", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPX1hDOEk5SWpudE1lNTFyOWxXemswcGt4WjJvWG05TUxzVGlVUzk3aENobFJlSlZHMjBnZzhGZVFETDUxRHBWcU93dXYzSnJXMGdCTEpIMy1BcjItTmd5dU9XY252azNjZ0JGb1l0eWVvMzFBZDV4dmFocmQ3ZDZtVmJJRXBYek12Mkp2cWw1a3JoVi03UGZOZUYxbVJrYzUz?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 59, "sentiment_summary": {"positive": 20, "negative": 4, "neutral": 35, "score": 56, "total": 59, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.75, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 9.35, "count": 19}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 2.2, "count": 4}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 20, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 13.81, "latest_week": "2026-07-17", "one_week_move": -9.4, "four_week_move": 0.4, "twelve_week_move": -37.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.697834, "market_dynamics_buy_signal": false, "relative_strength": -34.502626, "fair_value_gap": -2.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.5868, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.4% over one week, +0.4% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 7}, {"label": "Quartr", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "GuruFocus", "count": 3}, {"label": "Stock Traders Daily", "count": 3}, {"label": "BioSpace", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 51}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 19}, {"label": "Regulatory and legal", "count": 4}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "51", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.4% over one week, +0.4% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale"}], "updated_at": "2026-07-18T10:53:20.294873+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}